Side-by-side · Research reference

GHRP-2vsGonadorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED15/42 cited

BFDA-ApprovedHUMAN-REVIEWED7/61 cited

GHRP-2

Hexapeptide GHRP · Phase 2 (clinical diagnostic)

100–300 mcgPer doseBowers 1990

Phase 2Evidence levelBowers 1990 Sigalos 2018

~30 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

Gonadorelin

GnRH Analogue · Diagnostic & Therapeutic

90 minPulsatile interval

73%Ovulation restorationTadesse 2026

2–4 minPlasma half-life

IV / SQ · Pulsatile Pump (Therapeutic) · Single Bolus (Diagnostic)

01Mechanism of Action

Parameter

GHRP-2

Gonadorelin

Primary target

Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990

GnRH receptors on anterior pituitary gonadotropes

Pathway

GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002

GnRH → Pituitary gonadotrope → LH/FSH secretion → Gonadal steroidogenesisSharma 2026

Downstream effect

Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002

Pulsatile LH/FSH release stimulates testicular testosterone or ovarian estradiol/progesterone synthesis; initiates folliculogenesis and spermatogenesisRobin 2026 Sharma 2026

Feedback intact?

Yes, with somatostatin feedback active

Yes — pulsatile delivery preserves negative feedback loops; continuous exposure desensitizes receptors

Origin

Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990

Synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to native hypothalamic GnRH

Antibody development

—

02Dosage Protocols

Parameter

GHRP-2

Gonadorelin

Standard dose

100–300 mcg per injectionBowers 1990

—

Frequency

1–3× per day

—

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 2 + clinical diagnostic useBowers 1990

RCT / Expert consensus

Duration

8–12 weeks on / 4 off (anecdotal)

Continuous until pregnancy achieved or fertility goals met

3–6 month courses typical for ovulation induction.

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep + fasted preferred

—

Half-life

~30 minMalagón 1999

2–4 minutes (plasma)

Necessitates frequent pulsatile administration.

Diagnostic test (pituitary function)

—

100 mcg IV or SQ bolus

Measure baseline LH/FSH, then 30/60/90 min post-injection. Normal response: LH ≥2× baseline.

Therapeutic (hypothalamic hypogonadism)

—

5–20 mcg IV bolus every 90–120 minutes

Requires portable pulsatile pump. Dose individualized to achieve normal gonadotropin pulsatility.Robin 2026

Pulsatile interval

—

90 minutes (females) · 120 minutes (males)

Mimics physiological GnRH pulse frequency.

Route

—

IV preferred (therapeutic) · SQ acceptable (diagnostic)

Alternative protocols

—

Exogenous gonadotropins (hCG/hMG) often preferred due to convenience vs pump requirement

03Metabolic / Fat Loss Evidence

Parameter

GHRP-2

Gonadorelin

Fat loss mechanism

—

None — gonadorelin acts exclusively on reproductive axis

Indirect metabolic effects

—

Restoration of sex hormones may normalize body composition in hypogonadal states

Effect mediated by downstream testosterone/estradiol, not GnRH itself.

04Side Effects & Safety

Parameter

GHRP-2

Gonadorelin

Cortisol elevation

Mild but measurableBowers 1990

—

Prolactin elevation

Mild but measurable

—

Hunger

Strong appetite increase

—

Injection site reaction

Mild erythema

Erythema, irritation (pulsatile pump catheter site)

IGF-1 elevation

Strong; monitor with chronic high-dose use

—

Cancer risk

Contraindicated in active malignancy

—

Pregnancy / OB

Avoid

—

Headache

—

Common with bolus administration

Nausea / abdominal discomfort

—

Transient, dose-related

Ovarian hyperstimulation syndrome (OHSS)

—

Risk with ovulation induction protocols; monitor follicular development via ultrasound

Multiple gestation

—

Increased risk with fertility protocols (twins ~10–15%)

Anaphylaxis

—

Rare hypersensitivity reaction

Pump malfunction / infection

—

Mechanical failure or catheter-site infection with long-term IV pump use

Receptor desensitization

—

Continuous (non-pulsatile) exposure paradoxically suppresses gonadotropinsRobin 2026

Absolute Contraindications

GHRP-2

·Active malignancy
·Pregnancy / breastfeeding

Gonadorelin

·Pregnancy (except therapeutic infertility protocols)
·Hypersensitivity to gonadorelin or excipients
·Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation

Relative Contraindications

GHRP-2

·Untreated diabetes

Gonadorelin

·Ovarian cysts or PCOS (monitor for OHSS)
·Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)

05Administration Protocol

Parameter

GHRP-2

Gonadorelin

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

Administer 100 mcg IV or SQ bolus. Draw baseline LH/FSH, then at 30, 60, 90 minutes. Normal response: LH ≥2× baseline, FSH modest rise. Blunted response suggests pituitary pathology; exaggerated response may indicate primary hypogonadism.

2. Injection site

SQ — abdomen or thigh. Rotate sites.

Requires programmable infusion pump with IV catheter. Set pulse interval to 90 min (females) or 120 min (males). Bolus dose 5–20 mcg per pulse. Pump worn continuously; catheter site rotated every 48–72 hrs to prevent infection.

3. Timing

Pre-sleep + fasted preferred.

Lyophilised gonadorelin reconstituted with sterile saline or provided diluent. Typically 0.8–3.2 mg dissolved in 8 mL for pump reservoir. Solution stable 7–14 days refrigerated.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

For fertility protocols: ultrasound follicular tracking + serial estradiol/LH measurements. Adjust pulse dose to achieve mid-follicular LH 5–10 IU/L. Ovulation confirmed by progesterone rise or ultrasound.

5. Needle

29–31G, 4–8 mm insulin syringe.

Pulsatile therapy initiated at any point in cycle. Diagnostic test performed in morning (higher baseline LH). For ovulation induction, treatment begins early follicular phase.

06Stack Synergy

GHRP-2

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

GHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.

GHRP-2: 100–200 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: High-amplitude GH pulse, body composition

Bowers 1990 Teichman 2006

Gonadorelin

+ hCG (Human Chorionic Gonadotropin)

Multi-pathway

View hCG (Human Chorionic Gonadotropin) →

In hypogonadotropic hypogonadism protocols, gonadorelin restores pituitary LH/FSH pulsatility, while exogenous hCG directly stimulates Leydig cells (acting as LH mimetic) to maintain testosterone production. This dual approach ensures both central axis restoration and immediate gonadal steroidogenesis, preventing testicular atrophy during fertility treatment. hCG's longer half-life (24–36 hrs) complements gonadorelin's pulsatile short-acting profile.

Gonadorelin: 5–10 mcg IV every 120 min (pulsatile pump)
hCG: 1500–2000 IU SQ · 2–3× per week
Duration: 12–24 weeks for spermatogenesis induction
Primary benefit: Fertility restoration in hypothalamic hypogonadism with maintained testicular function